The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Newer-Generation Antiepileptic Drugs and the Risk of Major Birth Defects
Abstract
CONTEXT: Epilepsy during pregnancy is a therapeutic challenge. Since the 1990s, the number of licensed antiepileptic drugs has substantially increased, but safety data on first-trimester use of newer-generation antiepileptic drugs and birth defects are limited. OBJECTIVE: To study the association between fetal exposure to newer-generation antiepileptic drugs during the first trimester of pregnancy and the risk of major birth defects. DESIGN, SETTING, AND PARTICIPANTS: Population-based cohort study of 837,795 live-born infants in Denmark from January 1, 1996, through September 30, 2008. Individual-level information on dispensed antiepileptic drugs to mothers, birth defect diagnoses, and potential confounders were ascertained from nationwide health registries. MAIN OUTCOME MEASURES: Prevalence odds ratios (PORs) of any major birth defect diagnosed within the first year of life by fetal exposure to antiepileptic drugs. RESULTS: Of the 1532 infants exposed to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam during the first trimester, 49 were diagnosed with a major birth defect compared with 19,911 of the 836,263 who were not exposed to an antiepileptic drug (3.2% vs 2.4%, respectively; adjusted POR [APOR], 0.99; 95% confidence interval [CI], 0.72-1.36). A major birth defect was diagnosed in 38 of 1019 infants (3.7%) exposed to lamotrigine during the first trimester (APOR, 1.18; 95% CI, 0.83-1.68), in 11 of 393 infants (2.8%) exposed to oxcarbazepine (APOR, 0.86; 95% CI, 0.46-1.59), and in 5 of 108 infants (4.6%) exposed to topiramate (APOR, 1.44; 95% CI, 0.58-3.58). Gabapentin (n = 59) and levetiracetam (n = 58) exposure during the first trimester was uncommon, with only 1 (1.7%) and 0 infants diagnosed with birth defects, respectively. CONCLUSION: Among live-born infants in Denmark, first-trimester exposure to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam compared with no exposure was not associated with an increased risk of major birth defects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meador, K., Reynolds, M. W., Crean, S., Fahrbach, K., & Probst, C. (2008) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.04.022 · Cited by 400
Cited by
Guidelines for the Evaluation and Management of Status Epilepticus
Neurocritical Care Society Status Epilepticus Guideline Writing Committee, Brophy, G. M., Bell, R., Claassen, J., Alldredge, B., Bleck, T. P., Glauser, T., LaRoche, S. M., Riviello, J. J., Shutter, L., et al. (2012) · Neurocritical Care · doi:10.1007/s12028-012-9695-z · Cited by 1,623
Allison, D. B., Gadde, K. M., Garvey, W. T., Peterson, C. A., Schwiers, M. L., Najarian, T., Tam, P. Y., Troupin, B., & Day, W. W. (2012) · Obesity · doi:10.1038/oby.2011.330 · Cited by 711
Comparative safety of antiepileptic drugs during pregnancy
Hernández-Díaz, S., Smith, C. R., Shen, A., Mittendorf, R., Hauser, W. A., Yerby, M., Holmes, L. B., For the North American AED Pregnancy Registry, North American AED (Antiepileptic Drug) Pregnancy Registry, Cragan, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182574f39 · Cited by 620
Calcium channel auxiliary α2δ and β subunits: trafficking and one step beyond
Dolphin, A. C. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3311 · Cited by 368
Dolphin, A. C. (2016) · The Journal of Physiology · doi:10.1113/jp272262 · Cited by 352
Metadata
- Authors
- Mølgaard-Nielsen, D., & Hviid, A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2011-05-18
- Volume
- 305
- Issue
- 19
- Pages
- 1996-2002
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1976797456
- Cited by
- 248
- References
- 1
- FWCI
- 28.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Newer-Generation Antiepileptic Drugs and the Risk of Major Birth Defects. https://app.cochat.ai/papers/10.1001/jama.2011.624
- The paper
- Mølgaard-Nielsen, D., & Hviid, A. (2011). Newer-Generation Antiepileptic Drugs and the Risk of Major Birth Defects. JAMA. https://doi.org/10.1001/jama.2011.624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.